Objective & Hypothesis:Aim: In cases with acute ischemia, albumin’s binding capacity for transition metals decreases and the resulting albumin is defined as ischemia modified albumin (IMA).
📊
Key Findings & Data:In this study, we aimed to investigate the relationship between IMA and clinical follow-up in patients with acute renal failure (ARF).Material and Methods: Levels of IMA were measured in 51(23 male, 28 female) patients with ARF.
💡
Conclusion & Impact:The survival rates of patients in IMA
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Aim: In cases with acute ischemia, albumin’s binding capacity for transition metals decreases and the resulting albumin is defined as ischemia modified albumin (IMA). In this study, we aimed to investigate the relationship between IMA and clinical follow-up in patients with acute renal failure (ARF).Material and Methods: Levels of IMA were measured in 51(23 male, 28 female) patients with ARF. Venous blood samples were drawn from patients for biochemical tests and put in plain tubes containing the gel.Results: Mean age of male and female patients was 65.39±15.28 and 70.11±15.25, respectively. The IMA levels in 25.5% of the patients were within the normal range (400 ABSU) in 75.5% of the patients. The survival rates of patients in IMA
🔖
Cite This Article
AKAR, H., DUMAN, C., KARAKAS, B., TURKON, H., TOPALOGLU, O., UZUN, M., TANRİSEV, M., KURTULMUŞ, Y. (2022). Ischemia modified albumin levels and its association with clinical follow-up in acute renal failure. İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi, Cilt: 24 - Sayı: 3, 310–315. https://ajindex.com/articles/549642
Wu AH. The ischemia-modified albumin biomarker for myocardial ischemia. MLO Med Lab Obs 2003;35(6):36-8.
Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med 2004;35:1-5.
Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischaemia modified albumin is a sensitive marker of myocardial ischaemia after percutaneous coronary intervention. Circulation 2003;107(19):2403-5.
Sanchez LG, Mosquera AB, Sinha MK, Collinson PO, Gaze DC, Kaski JC. Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels 2008;23(3):174-80.
Yücel H, Türkdoğan KA, Zorlu A, Aydın H, Kurt R, Yılmaz MB. Association between oxidative stress index and post-CPR early mortality in cardiac arrest patients: A prospective observational study. Anatol J Cardiol 2015;15(9):747-53.
Carrega L, Giaime P, Montserrat C, Vincente O, Brunet P, Dussol B, et al. Influence of the dialysis membrane on markers of tissue ischemia. J Investig Med 2006;54(2):62-6.
Türedi S, Çınar O, Yavuz İ, Menteşe A, Gündüz A, Karahan SC, et al. Differences in ischemia-modified albuminlevels between end stage renal disease patients and the normal population. J Nephrol 2010:23(3):335-40.
Türkmen K, Tonbul HZ, Toker A İ, Gaipov A, Erdur FM, Çiçekler H, et el. The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients.Ren Fail 2012;34(10):1229-37.
Molitoris BA, Levin A, Warnock DG, Joannidis M, Mehta RL, Kellum JA, et al. Improving outcomes from acute kidney injury. J Am Soc Nephrol 2007;18(7):1992-4.
Sharfuddin AA, Weisbord SD, Palevsky PM, Molitoris BA. Acute Kidney Injury. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu SLA, Brenner BM, eds. Brenner and Rector’s The Kidney. 9th ed. New York: Elsevier; 2011. p. 1044-99.
Bar-Or D, Lau E, Rao N, N Bampos, JV Winkler, CG Curtis. Reduction in the cobalt binding capacity of human albumin with myocardial ischemia. Ann Emerg Med 1999;34(4):56 Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11(2):R31 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Group. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consens